| HOME >> MEDICINE >> TECHNOLOGY |
743,000General and administrative expenses
1,234,000
1,504,000Research and development costs
870,000
1,069,000Total operating expenses
2,700,000
3,316,000Income (loss) from continuing operations before items below
(431,000)
39,000Other expense:Interest expense
(6,000)
(20,000)Total other expense
(6,000)
(20,000)Income (loss) from continuing operations before provision for (benefit from) income taxes
(437,000)
19,000Provision for (benefit from) income taxes
(19,000)
2,000Income (loss) from continuing operations
(418,000)
17,000Income from discontinued operations, net of provision for income taxes of $25,000 in 2012 and $0 in 2011
53,000
137,000Net income (loss)
$
(365,000)
$
54,000Per share data:Income (loss) from continuing operationsBasic
$
(0.13)
$
.01Diluted
$
(0.13)
$
.01Income from discontinued operationsBasic
$
.02
$
.04Diluted
$
.02
$
.04Net income (loss)Basic
$
(0.11)
$
.05Diluted
$
(0.11)
$
.05Weighted average shares outstanding - basic
3,299,379
3,272,350Weighted average shares outstanding - diluted
3,299,379
3,292,508
PRO-DEX, INC. and SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS For The Six Months Ended December 31,2012
2011Cash flows from operating activities:Net income (loss)
$
(365,000)
$
54,000Adjustments to reconcile net income (loss) to net cash used in operating activities:Depreciation and amortization
298,000
339,000Allowance for doubtful accounts
(3,000)
6,000Share-based compensation
65,0
'/>"/>
| SOURCE Pro-Dex, Inc. Copyright©2012 PR Newswire. All rights reserved |